Wedbush Positive on Alexion (ALXN) Amid Achillion Acquisition
Tweet Send to a Friend
Wedbush analyst Laura Chico reiterated an Outperform rating and $146.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


